Key Details
Price
$1.01Annual ROE
-51.39%Beta
2.25Events Calendar
Next earnings date:
Feb 14, 2025Recent quarterly earnings:
Nov 6, 2024Recent annual earnings:
Feb 15, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Dec 11, 24 JMP Securities
Market OutperformNov 8, 24 HC Wainwright & Co.
BuyOct 28, 24 HC Wainwright & Co.
BuySep 19, 24 HC Wainwright & Co.
BuySep 16, 24 JMP Securities
Market OutperformSep 16, 24 HC Wainwright & Co.
NeutralSep 10, 24 HC Wainwright & Co.
NeutralAug 15, 24 HC Wainwright & Co.
NeutralMar 13, 24 JMP Securities
Market OutperformFeb 20, 24 HC Wainwright & Co.
NeutralMarket Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Price
Market cap
Technical
Dividend
Prelude Therapeutics Incorporated doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Leverage
Risk & Stability
Balance Sheet
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Assets
Equity
Liabilities
Debt
Expenses
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
Down -39.13% in 4 Weeks, Here's Why You Should You Buy the Dip in Prelude Therapeutics (PRLD)
PRLD
zacks.comNovember 11, 2024
Prelude Therapeutics (PRLD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024
PRLD
globenewswire.comSeptember 9, 2024
PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation oral session presentation: September 13, 2024, 4:00 PM CEST (10:00 AM EST)
Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
PRLD
globenewswire.comAugust 12, 2024
Interim Phase 1 data for its first-in-class, highly selective IV SMARCA2 degrader, PRT3789, selected for an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024 in September
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
PRLD
globenewswire.comJune 3, 2024
WILMINGTON, Del., June 03, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in two upcoming healthcare conferences in June.
All You Need to Know About Prelude Therapeutics Incorporated (PRLD) Rating Upgrade to Buy
PRLD
Zacks Investment ResearchOctober 4, 2023
Prelude Therapeutics Incorporated (PRLD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference
PRLD
GlobeNewsWireApril 11, 2023
Eight Abstracts Demonstrate Progress of Prelude's Differentiated Pipeline Eight Abstracts Demonstrate Progress of Prelude's Differentiated Pipeline
FAQ
- What is the ticker symbol for Prelude Therapeutics Incorporated?
- Does Prelude Therapeutics Incorporated pay dividends?
- What sector is Prelude Therapeutics Incorporated in?
- What industry is Prelude Therapeutics Incorporated in?
- What country is Prelude Therapeutics Incorporated based in?
- When did Prelude Therapeutics Incorporated go public?
- Is Prelude Therapeutics Incorporated in the S&P 500?
- Is Prelude Therapeutics Incorporated in the NASDAQ 100?
- Is Prelude Therapeutics Incorporated in the Dow Jones?
- When was Prelude Therapeutics Incorporated's last earnings report?
- When does Prelude Therapeutics Incorporated report earnings?
- Should I buy Prelude Therapeutics Incorporated stock now?
What is the ticker symbol for Prelude Therapeutics Incorporated?
The ticker symbol for Prelude Therapeutics Incorporated is NASDAQ:PRLD
Does Prelude Therapeutics Incorporated pay dividends?
No, Prelude Therapeutics Incorporated does not pay dividends
What sector is Prelude Therapeutics Incorporated in?
Prelude Therapeutics Incorporated is in the Healthcare sector
What industry is Prelude Therapeutics Incorporated in?
Prelude Therapeutics Incorporated is in the Biotechnology industry
What country is Prelude Therapeutics Incorporated based in?
Prelude Therapeutics Incorporated is headquartered in United States
When did Prelude Therapeutics Incorporated go public?
Prelude Therapeutics Incorporated's initial public offering (IPO) was on September 25, 2020
Is Prelude Therapeutics Incorporated in the S&P 500?
No, Prelude Therapeutics Incorporated is not included in the S&P 500 index
Is Prelude Therapeutics Incorporated in the NASDAQ 100?
No, Prelude Therapeutics Incorporated is not included in the NASDAQ 100 index
Is Prelude Therapeutics Incorporated in the Dow Jones?
No, Prelude Therapeutics Incorporated is not included in the Dow Jones index
When was Prelude Therapeutics Incorporated's last earnings report?
Prelude Therapeutics Incorporated's most recent earnings report was on Nov 6, 2024
When does Prelude Therapeutics Incorporated report earnings?
The next expected earnings date for Prelude Therapeutics Incorporated is Feb 14, 2025
Should I buy Prelude Therapeutics Incorporated stock now?
As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions